News

Innovative Gene Therapy Data Presentation at AHA 2025 Event

Innovative Gene Therapy Data Presentation at AHA 2025 Event

Tenaya Therapeutics Shines at AHA 2025

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a pioneering clinical-stage biotechnology firm, is set to make significant waves at the upcoming American Heart Association (AHA) Scientific Sessions in 2025. This event promises to be a major platform for innovative advancements in genetic therapies aimed at addressing heart disease.

Presentations Highlight Cutting-Edge Research

During the AHA event, Tenaya will conduct two late-breaking oral presentations that focus on its promising gene therapy products, particularly TN-201. This investigational therapy aims to tackle myosin-binding protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), a condition recognized for its severe impact on heart function due to the deficiency of MyBP-C.

Key Insights from the MyPEAK-1 Trial

The data to be presented from the MyPEAK-1 Phase 1b/2a trial will encompass crucial interim safety and efficacy results. These findings are anticipated to showcase the potential of TN-201 in improving patient outcomes for those suffering from HCM.

Details of the Oral Presentation

Presentation Title: TN-201, an Investigational MYBPC3 Gene Replacement Therapy: Interim Clinical Data from MyPEAK-1, a Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201 in Adult Patients with MYBPC3-Associated Hypertrophic Cardiomyopathy
Session Type: Late-Breaking Science: Main Event (Oral Presentation)
Session Title: Forgotten No More: The Current Belle of the Ball? Breakthrough Evolutions in Hypertrophic Cardiomyopathy
Presenter: Milind Y Desai, M.D., MBA, renowned for his work in cardiology.

Advancements in Ischemic Heart Failure Research

In addition to the TN-201 results, Tenaya will present groundbreaking findings related to cellular reprogramming treatments demonstrated in a preclinical pig model of ischemic heart failure. This innovative approach aims to regenerate cardiac cells, presenting a potential paradigm shift in the treatment of heart injuries stemming from ischemic events.

Details on the Cellular Reprogramming Presentation

Presentation Title: First Demonstration of Significant and Durable Improvement of Cardiac Function in Pig Model of Ischemic Heart Failure with Direct Reprogramming Delivered Precisely to Infarct Border via Guided Intramyocardial Injection Catheter
Session Type: Late-Breaking Basic Science (Oral Presentation)
Session Title: Next-Generation Therapies for Ischemic Heart Repair: From Cells to Imaging
Presenter: Kathy Ivey, Senior VP of Research at Tenaya Therapeutics.

Conference Call and Webcast

As part of the AHA experience, Tenaya will follow up with a conference call to discuss the TN-201 data showcased during the sessions. This call will occur on a designated date, allowing investors and analysts to delve deeper into the implications of the data presented.

About Tenaya Therapeutics

Tenaya Therapeutics remains dedicated to developing potentially curative therapies for heart diseases. The company emphasizes its commitment to utilizing advanced technologies in gene therapy, with strong candidates like TN-201 and TN-401 in its pipeline.

Frequently Asked Questions

What is the purpose of TN-201?

TN-201 is a gene replacement therapy aimed at treating hypertrophic cardiomyopathy associated with MYBPC3 deficiency.

When will the results be presented?

The presentations will occur during the AHA Scientific Sessions 2025, specifically on November 8 and 9, 2025.

How can I access the presentations?

Copies of the presentations will be available in the "Our Science" and "Investors" sections of the Tenaya Therapeutics website post-event.

Who is leading the research on TN-201?

The research is led by Dr. Milind Y Desai from the Cleveland Clinic, specializing in heart and vascular health.

What other therapies is Tenaya developing?

In addition to TN-201, Tenaya is also focused on gene therapies for other heart conditions, such as PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 167

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 86

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 100

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 86

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 278

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Painter's Accessory Aims to Revolutionize Convenience

Updated Category News Views 30

Crafty New Invention Targets Painters' Ease Ever find yourself tangled in paintbrushes and rollers while trying to get that perfect coat on the wall? Well, a painter from Bracebridge, Ontario, has had it with the struggle and is looking to stir the pot with their latest invention, the NU LIFE LINER. It's sleek, it's practical, and it's aimed at flipping the painting game...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 101

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 62

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading

Top 5 Most Recently Viewed Articles

Aptiv Plans Strategic Split to Strengthen Innovation and Growth

Updated Category News Views 783

Aptiv's Transformative Separation Announcement Aptiv PLC (NYSE: APTV), a pioneering technology company focused on creating a safer and more connected future, has officially unveiled plans to separate its Electrical Distribution Systems (EDS) business. This strategic decision, unanimously approved by the Board of Directors, sets the stage for both Aptiv and EDS to operate...

Continue Reading
e& Reports Strong Q3 2025 with Record Revenue and Growth

Updated Category News Views 364

Impressive Growth for e& in Q3 2025 e& has unveiled its Q3 2025 financial summary, showcasing robust growth with consolidated revenues soaring to AED 18.6 billion. This marks an impressive year-over-year growth of 29.2%. The momentum isn't just limited to the quarter; for the first nine months of 2025, the company reported consolidated revenues of AED 53.5 billion,...

Continue Reading
PARRIS Law Firm Achieves Prestigious Trial Awards for 2024 Success

Updated Category News Views 242

Acknowledging PARRIS Law Firm's Impressive Recognition in 2024 PARRIS Law Firm, renowned for its excellence in trial advocacy, has just earned multiple accolades from Top Verdict for its remarkable performances in 2024. With several No. 1 verdicts in various categories, this year marks another milestone for the firm as it stands tall among California's premier legal...

Continue Reading
Insights into the Latest Riksbank Certificate Auction Results

Updated Category News Views 232

Overview of the Riksbank Certificate Auction The recent auction conducted by the Riksbank has revealed significant details regarding certificate sales that are vital for investors and market analysts. The auction concluded successfully, showcasing the Riksbank's strategies and market engagement. Auction Details and Financial Impact Key Dates and Interest Rates The auction...

Continue Reading
Alamar Biosciences Unveils Advanced NULISAqpcr Custom Assay Kit

Updated Category News Views 205

Alamar Biosciences Introduces the NULISAqpcr™ Custom Assay Development Kit Alamar Biosciences has unveiled a significant innovation in the field of precision proteomics with the launch of the NULISAqpcr™ Custom Assay Development Kit. This groundbreaking product allows researchers to develop highly sensitive biomarker assays tailored to their specific research needs....

Continue Reading